Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645593 · ClinicalTrials.gov registry record · Phase 2
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT00645593 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 89 participants.
The verdict
NCT00645593, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This study will compare the effects, good and/or bad, of chemotherapy (Gemcitabine and Cisplatin) with or without the addition of the chemotherapy drug Cetuximab to find out which treatment is better.
Interventions
- DRUG Cisplatin
- DRUG Cetuximab
- DRUG Gemcitabine,
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-03 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645593
The ClinicalTrials.gov registry entry for NCT00645593 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00645593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00645593 about?
NCT00645593 is a clinical study titled "Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer". This study will compare the effects, good and/or bad, of chemotherapy (Gemcitabine and Cisplatin) with or without the addition of the chemotherapy drug Cetuximab to find out which treatment is better.
What is the current status of trial NCT00645593?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2008-03. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00645593?
The interventions under investigation include: Cisplatin (DRUG), Cetuximab (DRUG), Gemcitabine, (DRUG).
Who is sponsoring clinical trial NCT00645593?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.